New PBS listings from 1 Feb 2020
From 1 February 2020, there are several new and amended PBS listings that have impacted authority application forms and the process to request authority approvals.
These changes include the following:
- PBS-subsidised tezacaftor + ivacaftor restriction for cystic fibrosis who have at least one RF mutation
The PBS listing of tezacaftor + ivacaftor for cystic fibrosis has been amended to include patients age 12 years and older who have at least one RF mutation in the CFTR gene.
The cystic fibrosis web page and associated authority application form(s) have been updated to reflect the amended PBS restrictions.
- PBS-subsidised sapropterin for hyperphenylalaninemia (HPA)
The PBS listing of sapropterin for hyperphenylalaninemia (HPA) due to BH4 deficiency is Authority Required (Telephone).
You can either request authority approval using Online PBS Authorities in HPOS, or call the PBS authority approvals enquiry line. The BH4 deficiency web page has been updated to reflect the amended PBS restrictions.
- From 1 January 2020, verteporfin for the treatment of Subfoveal choroidal neovascularisation is no longer be subsidised through the PBS.
For more information and to access the updated authority application forms, please visit Services Australia website.
For further information on new and amended PBS listings, please visit the PBS website and PBS summary of changes.
